Abstract: Since it was first described by Kossard in 1994, frontal fibrosing alopecia (FFA) has been something of an enigma. The clinical heterogeneity of FFA, its apparent rarity, and investigators' suboptimal access to phenotypically consistent patient cohorts, may all have had a negative impact on delineating disease pathogenesis. Moreover, there is a relative paucity of epidemiologic interventional and basic research studies, and there have been no advances in translational therapeutics, unlike for other inflammatory dermatoses, such as alopecia areata (AA). Dermatologists anecdotally describe an increasing incidence in FFA over the last decade, which has led to the notion that the disorder may be induced by unknown environmental triggers. On the other hand, segregation of FFA in some families lends support to an unexplored genetic element implicated in disease pathogenesis. We herein review what is known about the pathobiology of FFA and formulate working hypotheses to advance insight into this intriguing hair disorder.
Introduction
Cicatricial or scarring alopecias, whether primary or secondary, are a therapeutically challenging problem in clinical practice. Primary cicatricial alopecias (PCA) represent a rather diverse group of inflammatory disorders, where the common denominator, in pathologic terms, is the irreversible destruction of hair follicles. Frontal Fibrosing Alopecia (FFA) is a recently described, predominantly postmenopausal, primary lymphocytic cicatricial alopecia (1) that has been thought to be a variant of lichen planopilaris (LPP) (2) . Clinically, the disorder involves the frontotemporal hairline with perifollicular erythema, follicular hyperkeratosis and scarring with evident hairline recession, although clinical signs of inflammation are not always evident (3) . Eyebrow loss is recorded in 50%-83% of cases (3) (4) (5) but body hair loss has been less commonly reported, as has eyelash volume loss (0%-77%) (5) (6) (7) . The histology of FFA (Fig 1) is similar to that of classic (multifocal) LPP, with the early active stages showing a perifollicular lichenoid inflammatory infiltrate involving the isthmus and infundibulum; later stages are characterized by perifollicular fibrosis with follicular dropout and follicular scars replacing the pilosebaceous units (2, 8) . The inflammatory focal point in FFA is the bulge area of the hair follicle (HF) in contrast to alopecia areata (AA),
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where the bulb at the lower third of the HF is at the epicentre (9, 10) . The identical histological appearance accounts for the widespread acceptance of FFA as clinical subvariant of (follicular) lichen planus (11) .
Dividing PCAs histologically into lymphocytic, neutrophilic and mixed, has guided clinical classification but microscopic characterisation may not reflect upstream differences in pathogenesis. Neither do the histological similarities reflect clinical overlap: the classic pattern of LPP behaves differently clinically and epidemiologically from its rather distinct subvariant FFA: the latter has a striking clinical pattern of ear-to-ear scarring hair loss, often with eyebrow and body hair involvement and much commoner in postmenopausal women (12, 13) . Only rarely does FFA affect men whereas LPP does not show a gender or older age predilection. Of note, pediatric cases of LPP have also been reported, whereas FFA is unheard of in the pediatric population (14) .
The exact pathogenesis of FFA remains unknown. Its postmenopausal occurrence led to the speculation of a hormone-related triggering mechanism. Moreover, 5-alpha reductase inhibitors have been reportedly used with some success, although it has been argued that the beneficial effect of these may be on any concomitant androgenetic element of hair loss, while the overall evidence-basis for this claim remains poor (12, 15) . There have been familial cases of FFA reported in the literature (16) (17) (18) (19) but robust genetic analysis of the condition has not been undertaken to date.
The case for a genetic basis underlying FFA and the role of the environment
Genetic exploration has been instrumental in revealing molecular pathways underlying alopecic variants, such as Marie-Unna hypotrichosis (20) and alopecia areata (AA) (21), among other cutaneous disorders. It would therefore be prudent to consider the research question of whether there is genetic basis to be explored and, if so, what method would be more appropriate to employ in doing so.
The notion that FFA is underlain by a genetic element is supported primarily by evidence of disease segregation in first-degree relatives. We and others (16) (17) (18) (19) have reported familial cases of FFA, where the observed inheritance is in keeping with an autosomal dominant
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This article is protected by copyright. All rights reserved. Relative IP loss in anagen hair follicular epithelium is postulated to underlie the organspecific auto-immune disorder AA, where loss of relative IP leads to ectopic MHC class I expression and, as yet elusive, autoantigens trigger a CD8+T cell-mediated inflammatory process, microscopically seen as the classic peribulbar 'swarm of bees' (Fig 2) (34-36) .
The IP-privileged HF bulge is home to epithelial hair follicle stem cells (37) 
One immunohistochemical marker of EMT is Snail1 (61) which is expressed in the fibrotic dermis of individuals affected by FFA (62) , indicating that profibrotic cells may be derived at least in part by of EMT, where molecules such as TGFβ could be key. This makes one consider targeting such molecular regulators (or EMT-related miRNA) to arrest or reverse the fibrotic process, whether in skin, liver, lungs or kidneys.
Hormones and trauma: true culprits or mere helpers and enemies?
FFA is known to almost exclusively affect women of postmenopausal age (1, 2) . Of the 150 cases that currently are under our care, the vast majority developed the disorder after menopause, whereas the few younger female patients had iatrogenic, syndromic or biochemical estrogen decline prior to developing FFA (namely ovarectomy, Turner's syndrome or early menopause). Of course, disease chronicity is known to be associated with excessive fibrous tissue deposition, altered tissue architecture, and organ dysfunction and fibrosis per se increases in all organs with aging (63, 64) . Estrogen has been found to exert antifibrotic effects in vivo (65) and act as potent immunomodulator by suppressing central, innate and adaptive immunity in certain cell types (66), although its effects are known to be variable (67) . Does menopause simply coincide with the profibrotic processes of aging or does the menopausal estrogen decline cause unfavourable immunomodulation, thereby allowing a lifelong condition to declare itself and come to the fore? The latter may be in keeping with our observation that other body regions in people with FFA are hairless from a much younger age, thus predating the more intense manifestations of the disorder that occur much later. Male FFA may also be consistent with the above hypothesis: serum testosterone levels are known to decrease with ageing, as does its aromatase-induced conversion to estrogen (68, 69) . In either scenario, hormone replacement following realisation of disease activity would not possibly be capable to reverse the underlying process of immune privilege collapse and autoantigen driven lymphocytic attack.
The observation that hair transplantation and face-lift surgery re-activates the disease process (70-72) may also be in keeping with the above hypothesis: the disordered immunemediated collapse of the hair-follicle's privileged integrity may well leave local factors, such as memory T-cells in skin stroma. In line with this, when apparently normal autologous hair follicles are transplanted to a region previously involved with FFA, subjects can develop the
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histological hallmarks of the disease (73, 74) . Any traumatic or inflammatory insult or merely implanting more antigens by transplanting hairs in that stroma would be germane to stepping into an active but quiet minefield before the ensuing catastrophe becomes macroscopically and clinically noticeable.
Are there potential diagnostic markers or disease biomarkers for FFA?
MicroRNAs (miRNAs) are relatively recently discovered small, endogenous, non-coding ribonucleic acid molecules (RNAs) that affect various cellular processes underlying health and disease by exerting target gene expression regulatory functions (75, 76) . Recent years have seen miRNAs emerging as key determinants of organ phenotypes and potential candidates of prognostic, diagnostic and therapeutic interest in numerous disease processes (77) (78) (79) (80) (81) . Aberrant expression or function of miRNAs has been implicated in a broad spectrum of human disorders, such as several types of malignancy, neurodegenerative, infectious, metabolic, chronic inflammatory, fibrotic and autoimmune diseases (82) (83) (84) (85) (86) (87) (88) (89) and this has led to widespread attention to miRNAomics.
It has recently been discovered that miRNAs can be detected in plasma and serum, where they circulate in a stable form (90-92) mostly because of their encapsulation in serum microvesicles or exosomes (93) . There is relative paucity of microRNAomic investigations in cutaneous pathophysiology with the notable exception of psoriasis (94) rendering the prospect of exploring their potential usefulness in FFA and other related alopecic disorders a very attractive one and we are pursuing.
Proposed strategies for advancing insights into FFA
In order to dissect the molecular etiopathogenesis of FFA, a genomic investigation would need to explore if there is a genetic component underlying any observed heritability ( Table   1) . Whether rare coding alleles of large effect size determine FFA would best be addressed via deep sequencing affected familial cases. By studying related, highly clinically consistent individuals it is anticipated that the shared phenotype is caused by shared genetic variation, an approach that circumnavigates the problem of heterogeneity. Nevertheless, the vast majority of cases are sporadic and it would be important to explore whether common genetic variation or more complex pathways predispose to disease: a genome-wide
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The overall rare incidence argues against an environmental etiology as the sole pathogenic determinant, although carefully designed observational studies could examine this notion, ideally followed by epigenetic exploration.
Identifying a refined genetic or protein micro-entity as a biomarker would be indispensable to disease prognostication and could help optimise therapeutic strategies: circulating microRNA and metabolomic profiling may also be an appropriate approach but may be challenging to validate, given the slowly progressive nature of FFA requiring a prolonged and carefully controlled study. 
